Article

TTT trial to test potential treatment for wet AMD

Mountain View, CA-IRIDEX Corp. has completed enrollment in a clinical trial for its TTT4CNV, to determine whether trans-pupillary thermotherapy (TTT) laser treatment can reduce the risk of vision loss for patients with occult wet age-related macular degeneration (AMD).

Related Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Image credit: ©Ophthalmology Times
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
Related Content
Glaukos announces several positive clinical updates for its iDose platform
January 20th 2025

Glaukos announces several positive clinical updates for its iDose platform

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company
January 19th 2025

InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Ocugen doses first patient in phase 1 trial of OCU200 for treatment of diabetic macular edema
January 17th 2025

Ocugen doses first patient in phase 1 trial of OCU200 for treatment of diabetic macular edema

Inflammasome Therapeutics expands K8 trial following positive 3-month results
January 17th 2025

Inflammasome Therapeutics expands K8 trial following positive 3-month results

© 2025 MJH Life Sciences

All rights reserved.